Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.60 Consensus Target Price from Brokerages

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have received an average rating of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $6.1667.

A number of research firms have commented on CNTX. Lifesci Capital upgraded shares of Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. D. Boral Capital restated a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a research report on Tuesday, March 24th. Piper Sandler raised their price target on shares of Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 24th. Wall Street Zen downgraded shares of Context Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research report on Monday, April 20th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Virtu Financial LLC bought a new position in shares of Context Therapeutics in the 4th quarter worth about $43,000. Sanctuary Advisors LLC acquired a new stake in shares of Context Therapeutics in the 1st quarter worth about $51,000. Quadrature Capital Ltd acquired a new stake in shares of Context Therapeutics in the 4th quarter worth about $68,000. Citadel Advisors LLC acquired a new stake in shares of Context Therapeutics in the 3rd quarter worth about $100,000. Finally, XTX Topco Ltd increased its holdings in shares of Context Therapeutics by 858.8% in the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock worth $149,000 after acquiring an additional 91,008 shares during the period. 14.03% of the stock is currently owned by institutional investors.

Context Therapeutics Price Performance

NASDAQ CNTX opened at $0.60 on Thursday. Context Therapeutics has a 12 month low of $0.56 and a 12 month high of $3.62. The company has a market capitalization of $55.13 million, a price-to-earnings ratio of -1.43 and a beta of 1.61. The company’s fifty day moving average price is $2.22 and its two-hundred day moving average price is $2.09.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03. As a group, analysts anticipate that Context Therapeutics will post -0.35 EPS for the current year.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.